Komplikationen der Leberzirrhose – medikamentöse versus interventionelle Therapie

Abstract

The prognosis of patients with liver cirrhosis is impaired by complications such as variceal bleeding, ascites, hepatorenal syndrome, hepatic encephalopathy and hepatocellular carcinoma. A steadily increasing array of treatment options for these complications is available, including pharmaceutical treatment (e. g. beta blockers for varices or diuretics for ascites), endoscopic treatment (e. g. band ligation of varices), radiological interventions (e. g. transjugular shunt, transarterial chemoembolization) and liver transplantation. Most of the complications occur due to portal hypertension. Therefore, decompressive treatment by implantation of a transjugular intrahepatic portosystemic shunt (TIPS) an effective therapeutic option for many complications of liver cirrhosis. Its main indications are acute and recurrent variceal bleeding in patients with advanced disease as well as refractory ascites. The TIPS does not affect options of abdominal surgery and may therefore be used as a bridge to liver transplantation.

Die Leberzirrhose stellt das Endstadium einer chronischen Lebererkrankung dar. Die Pathophysiologie, Diagnostik und Therapie der Komplikationen füllt ganze Lehrbücher. Der folgende Artikel soll einen Überblick über die Therapie der wichtigsten Komplikationen der Leberzirrhose geben und sich insbesondere der Frage widmen, wann eine medikamentöse und wann eine interventionelle Therapie indiziert ist.

Schlüsselwörter

Leberzirrhose - Aszites - Varizenblutung - transjugulärer intrahepatischer portosystemischer Shunt

Key words

liver cirrhosis - ascites - variceal bleeding - transjugular intrahepatic portosystemic shunt

• Literatur

• 1 Schultheiß M, Bettinger D, Fichtner-Feigl S. et al. Hepatozelluläres Karzinom: neue multimodale Therapiekonzepte. Dtsch med Wochenschr 2018; 143: 815-819
• 2 Gerbes AL, Labenz J, Appenrodt B. et al. Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“. Z Gastroenterol 2019; 57 (05) 611-680 . doi:10.1055/a-0873-4658
• 3 Rössle M, Ochs A, Gülberg V. et al. A Comparison of Paracentesis and Transjugular Intrahepatic Portosystemic Shunting in Patients with Ascites. N Engl J Med 2000; 342: 1701-1707
• 4 Bureau C, Thabut D, Oberti F. et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology 2017; 152: 157-163
• 5 Hung TH, Tsai CC, Hsieh YH. et al. The Effect of the First Spontaneous Bacterial Peritonitis Event on the Mortality of Cirrhotic Patients with Ascites: A Nationwide Population-Based Study in Taiwan. Gut Liver 2016; 10: 803-807
• 6 de Franchis R. Baveno VI Faculty. Expanding consensus in portal hypertension. J Hepatol 2015; 63: 743-752
• 7 Reiberger T, Ulbrich G, Ferlitsch A. et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2013; 62: 1634-1641
• 8 Rössle M, Richter GM, Noeldge G. et al. Der intrahepatische portosystemische Shunt: Erste klinische Erfahrungen bei Patienten mit Leberzirrhose. Dtsch med Wochenschr 1989; 114 (40) 1511-1516 . doi: 10.1055/s-2008-1066789
• 9 Rössle M, Haag K, Ochs A. et al. The Transjugular Intrahepatic Portosystemic Stent-Shunt Procedure for Variceal Bleeding. N Engl J Med 1994; 330 (03) 165-171
• 10 Sauerbruch T, Mengel M, Dollinger M. et al. Prevention of Rebleeding From Esophageal Varices in Patients With Cirrhosis Receiving Small-Diameter Stents Versus Hemodynamically Controlled Medical Therapy. Gastroenterology 2015; 149: 660-668
• 11 Holster IL, Tjwa ET, Moelker A. et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology 2016; 63: 581-589
• 12 García-Pagán JC, Caca K, Bureau C. et al. Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. N Engl J Med 2010; 362: 2370-2379
• 13 Rössle M, Schultheiss M. Commentary on “Covered TIPS for secondary prophylaxis of variceal bleeding in liver cirrhosis: A systematic review and meta-analysis of randomized controlled trials”. AME Med J 2017; 2: 33
• 14 Stewart CA, Malinchoc M, Kim WR. et al. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transplant 2017; 13: 1366-1371
• 15 Córdoba J, López-Hellín J, Planas M. et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41: 38-43
• 16 Dam G, Vilstrup H, Watson H. et al. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. Hepatology 2016; 64 (04) 1265-1272 . doi: 10.1002/hep.28737
• 17 Sturm L, Bettinger D, Giesler M. et al. Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS). United European Gastroenterol J 2018; 6: 1380-1390
• 18 Rössle M, Euringer W. Hepatic Encephalopathy in Patients with Transjugular Intrahepatic Portosystemic Shunt (TIPS). In: Mullen KD, Prakash RK. Hrsg. Hepatic Encephalopathy. 1.. Aufl. Heidelberg: Springer; 2012: 211-220 DOI: 10.1007/978-1-61779-836-8
• 19 Kircheis G, Wettstein M, Timmermann L. et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002; 35: 357-366
• 20 Schultheiss M, Bettinger D, Boettler T. et al. Severe Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt (TIPS): Value of Shunt Reduction and Occlusion. JSM Hepat 2017; 2 (01) 1009
• 21 Salerno F, Cammà C, Enea M. et al. Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data. Gastroenterology 2007; 133 (03) 825-834